Carboxyl chalcone derivative as well as preparation method and application thereof
Carboxychalone derivatives were developed through the structural modification of chalone, which solved the side effects and risks of existing xanthine oxidase inhibitors, achieved efficient uric acid reduction effect, and simplified the preparation process, which was suitable for the industry .
Patent Information
- Application Number
- CN202411161417.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-23
AI Technical Summary
Existing xanthine oxidase inhibitors have side effects in the treatment of hyperuricemia and have high cardiovascular risk and liver function impairment. It is urgent to develop efficient and low-toxic alternative drugs.
By modifying the structure of the chalkone, carboxy chalkone derivatives were developed, and the A and B rings of the chalkone were modified with specific R1 and R2 groups to form a series of carboxy chalkone derivatives. Prepared by microwave catalytic reactions, new xanthine oxidase inhibitor candidate compounds are provided.
Carboxychalone derivatives significantly improve the inhibitory activity of xanthine oxidase, reduce the IC50 value by an order of magnitude, and show good uric acid reduction effects in animal experiments, the efficacy is comparable to allopurinol, and the process is simple and the cost is low. , suitable for industrial production.
Smart Images

Figure CN119039135A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical chemistry and relates to carboxyl chalcone derivatives and preparation methods and applications thereof. Background Art
[0002] Uric acid (UA) is the final oxidation product of purine decomposition in the human body. It is slightly soluble in water and easily forms crystals. Under normal circumstances, the production and excretion of uric acid in the body are in a balanced state. However, when UA is produced excessively and excretion is blocked, and the blood uric acid concentration is greater than 7 mg / dL, it will cause the body fluids to become acidic, urate crystals to form and accumulate in the tissues. In the long run, it will lead to hyperuricemia and even gout, and may also cause urate nephropathy, joint disability, and renal insufficiency. In the treatment of hyperuricemia, it is necessary to control the normalization of serum UA levels and maintain the urate level in the body in a steady state. Xanthine oxidase (XO) can catalyze the final hydroxylation of hypoxanthine to UA in the final step of UA synthesis. Therefore, one of the effective ways to treat hyperuricemia is to interfere with the production of UA by inhibiting the activity of XO.
[0003] Currently available XO inhibitors include allopurinol, febuxostat, and topiroxostat. Allopurinol is the longest-lasting and most widely used XO inhibitor to date, but its metabolite oxypurinol can significantly affect metabolism, causing side effects such as fever, allergic rash, abdominal pain, diarrhea, leukopenia and thrombocytopenia, and liver damage. Studies have shown that compared with the non-purine inhibitors febuxostat and topiroxostat, allopurinol has relatively higher efficacy and fewer adverse reactions. However, in many cases, febuxostat and topiroxostat have higher cardiovascular risks. In addition, febuxostat also has risks of liver function and rash, and topiroxostat may also increase the probability of liver damage. Therefore, it is urgent to explore highly effective and low-toxic XO inhibitors to treat hyperuricemia.
[0004] Natural products are an important source of novel bioactive compounds with therapeutic applicability. They have rich bioactive components, extensive utilization history and fewer adverse reactions. Among them, chalcone (1,3-diaryl-2-propene-1-one) is a natural aromatic ketone mainly found in plants. It consists of two aromatic rings (A ring and B ring) connected by an α, β-unsaturated carbonyl group. Its structural formula is
[0005] Chalcones with natural skeletons have advantages such as simple chemical structure and no obvious toxicity. They also have multiple pharmacological properties such as anti-cancer, anti-diabetic, antibacterial, antiviral, anti-inflammatory and antioxidant. Literature research shows that chalcones have certain XO inhibitory activity, but their XO inhibitory activity is not high and far from meeting the requirements of actual clinical application. Therefore, if more chalcone derivatives that can effectively inhibit XO activity can be discovered by structural modification of chalcone, more candidate compounds can be provided for the development of XO inhibitors, which will have a positive significance for the development of drugs for the treatment of hyperuricemia. Summary of the invention
[0006] The purpose of the present invention is to overcome the deficiencies of the prior art, provide carboxy chalcone derivatives and preparation methods and applications thereof, so as to effectively improve the activity of chalcone in inhibiting xanthine oxidase, and provide more candidate compounds for the development of xanthine oxidase inhibitors.
[0007] In order to achieve the above-mentioned invention object, the technical solution adopted by the present invention is as follows:
[0008] Carboxy chalcone derivatives, the general structural formula of the carboxy chalcone derivatives is shown in formula (I) or formula (II):
[0009]
[0010] In formula (I), R1 is methyl, ethyl, n-propyl, ethynyl, methylamino, dimethylamino, methylthio or methylsulfonyl;
[0011] In formula (II), R2 is 3-thiophene, 2-thiazole, dihydrobenzofuran, benzodioxolane, benzodioxane, indole, dihydroindole, quinoline or naphthalene.
[0012] In the technical solution of the above carboxy chalcone derivatives, the carboxy chalcone derivatives with the general structural formula shown in formula (I) or formula (II) are in trans (E) configuration.
[0013] In the technical scheme of the above-mentioned carboxy chalcone derivatives, the carboxy chalcone derivatives with a general structural formula as shown in formula (I) include compounds I-1 to I-8, and the structural formulas of compounds I-1 to I-8 are as follows:
[0014]
[0015] In the technical scheme of the above-mentioned carboxy chalcone derivatives, the carboxy chalcone derivatives with a general structural formula as shown in formula (II) include compounds II-1 to II-10, and the structural formulas of compounds II-1 to II-10 are as follows:
[0016]
[0017] The present invention also provides pharmaceutically acceptable salts of the above carboxyl chalcone derivatives, for example, addition salts formed by the above compounds I-1 to I-8, or compounds II-1 to II-10 and hydrochloric acid, hydrobromic acid, sulfuric acid, carbonic acid, citric acid, succinic acid, tartaric acid, phosphoric acid, lactic acid, pyruvic acid, acetic acid, maleic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid or ferulic acid.
[0018] The term "pharmaceutically acceptable" means that it is suitable for use in contact with the tissues of humans and other mammals without undue toxicity, irritation, allergic response, etc., within the scope of reasonable medical judgment, and can directly or indirectly provide a compound or prodrug of the compound of the present invention when administered to a recipient.
[0019] The present invention also provides a method for preparing the above-mentioned carboxy chalcone derivatives, and the synthetic route and steps of the method are as follows:
[0020]
[0021] ① dissolving compound 1 or compound 2 in a solvent to obtain a solution of compound 1 or compound 2, adjusting the pH value of the solution of compound 1 or compound 2 to 9-13, then adding 3-formyl-4-hydroxybenzoic acid methyl ester and mixing evenly to obtain a reaction precursor solution, and fully reacting under microwave conditions of 80-100° C. and 100-300W;
[0022] The compound 1 is p-methylacetophenone, p-ethylacetophenone, p-propylacetophenone, p-ethynylacetophenone, p-methylaminoacetophenone, p-dimethylaminoacetophenone, p-methylthioacetophenone or p-methylsulfonylacetophenone; the compound 2 is 3-acetylthiophene, 2-acetylthiazole, 5-acetyl-2,3-dihydrobenzofuran, 3',4'-methylenedioxyacetophenone, 6-acetyl-1,4-benzodioxetane, 1-(2,3-dihydro-1H-indol-5-yl)-ethanone, 5-acetylindole, 6-acetylquinoline, 2-acetylnaphthalene or 1-acetylnaphthalene;
[0023] In this step, the molar ratio of compound 1 or compound 2 to methyl 3-formyl-4-hydroxybenzoate is controlled to be (1-1.5):1;
[0024] ② removing the solvent of the reaction solution obtained after the reaction in step ① is completed to obtain a reaction product, dissolving the reaction product in water and washing it with ethyl acetate, adjusting the pH value of the obtained aqueous phase to 5-6, and then extracting it with ethyl acetate, washing the extracted organic phase with a saturated sodium chloride solution, then removing water, and evaporating to remove ethyl acetate to obtain a crude product; separating and purifying the crude product by silica gel column chromatography to obtain a carboxy chalcone derivative.
[0025] In step ② of the technical scheme of the preparation method of the above-mentioned carboxychalcone derivatives, when the crude product is separated and purified by silica gel column chromatography, a dichloromethane-methanol mixture is used as an eluent for gradient elution. In the dichloromethane-methanol mixture used for gradient elution, the volume ratio of dichloromethane to methanol gradually changes from 70:1 to 30:1.
[0026] In the technical scheme of the preparation method of the above-mentioned carboxychalcone derivatives, the solvent in step ① is water, methanol or ethanol.
[0027] In step ① of the technical solution for preparing the above-mentioned carboxychalcone derivatives, the concentration of compound 1 or compound 2 in the reaction precursor solution is preferably 0.05 to 0.1 mmol / mL.
[0028] In step ① of the technical solution of the above-mentioned method for preparing carboxychalcone derivatives, the pH value of the solution of compound 1 or compound 2 is adjusted to 9-13 using NaOH, KOH, sodium methoxide, sodium ethoxide, etc.
[0029] In step ② of the technical solution of the preparation method of the above-mentioned carboxychalcone derivatives, the removal of moisture can generally be carried out by drying with anhydrous Na2SO4 to remove moisture.
[0030] The present invention adopts a xanthine oxidase (XO) inhibitor screening model to detect the in vitro XO inhibition activity of carboxy chalcone derivatives (i.e., compounds I-1 to I-8, compounds II-1 to II-10), and allopurinol and febuxostat are used as positive control drugs respectively. The results show that compounds I-1 to I-8 and compounds II-1 to II-10 have excellent XO inhibition effects, and their in vitro XO inhibition activity is measured by IC 50 The values are between 0.064±0.023 and 0.226±0.011 μmol / L, while the IC value of allopurinol, which is widely used in clinical practice, in inhibiting XO activity in vitro is 50 The value is 2.588±0.206 μmol / L. In comparison, the IC values of compounds I-1 to I-8 and compounds II-1 to II-10 of the present application for inhibiting XO in vitro are 50 The value has dropped by an order of magnitude.
[0031] The present invention also tested the effect of the carboxyl chalcone derivative (Compound I-5) on serum uric acid in acute hyperuricemia model rats through animal experiments. The results showed that when Compound I-5 was orally administered at a dose of 40 mg / kg, it showed a good uric acid-lowering effect, which was comparable to that of the positive control group (the control group that took allopurinol orally). The serum uric acid level in this group was significantly different from that in the model group ( ****p<0.0001). This indicates that the carboxyl chalcone derivatives of the present invention (such as compound I-5) can also significantly inhibit the serum uric acid index of hyperuricemia in vivo and exert good anti-hyperuricemia activity.
[0032] Based on the above experimental results, the present invention also provides the use of the above carboxychalcone derivatives or the above carboxychalcone derivatives in pharmaceutically acceptable salts in the preparation of drugs targeting xanthine oxidase. Further, the drugs targeting xanthine oxidase include drugs for treating hyperuricemia.
[0033] Compared with the prior art, the present invention produces the following beneficial technical effects:
[0034] 1. The present invention provides a series of carboxyl chalcone derivatives based on chalcone, wherein a hydroxyl group and a carboxyl group are simultaneously introduced at the ortho and meta positions of the chalcone B ring, and a specific R1 or R2 group is introduced at the A ring of the chalcone for modification. The present invention has experimentally confirmed that the carboxyl chalcone derivatives (compounds I-1 to I-8 and compounds II-1 to II-10) provided by the present invention have excellent XO inhibition effects, and their in vitro XO inhibition activities are measured in terms of IC 50 The values were between 0.064±0.023 and 0.226±0.011 μmol / L, which is comparable to the IC value of allopurinol, which is widely used in clinical practice, for inhibiting XO in vitro. 50 The value is reduced by one order of magnitude. At the same time, the carboxyl chalcone derivatives (such as compound I-5) provided by the present invention can effectively reduce the serum uric acid level of rats with acute hyperuricemia model, and its effect is equivalent to that of allopurinol, and can be used in the preparation of drugs targeting xanthine oxidase. The present invention provides a new candidate compound for the research and development of drugs for treating hyperuricemia.
[0035] 2. The present invention also provides a method for preparing carboxy chalcone derivatives. The preparation method has a simple process and adopts microwave catalytic reaction, which greatly shortens the synthesis cycle, and can obtain the product through a "one-pot method". The reaction conditions are mild and the cost is low. It is suitable for industrial production and is conducive to popularization and application. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 The figure is the change curve of serum uric acid concentration over time after administration of the blank group (Blank), model group (Model), allopurinol group (Allopurinol (40 mg / kg)), compound I-5 low-dose group (I-5 (10 mg / kg)), compound I-5 medium-dose group (I-5 (20 mg / kg)) and compound I-5 high-dose group (I-5 (40 mg / kg)).
[0037] Figure 2 It is the serum uric acid concentration of blank group (Blank), model group (Model), allopurinol group (Allopurinol (40 mg / kg)), compound I-5 low-dose group (I-5 (10 mg / kg)), compound I-5 medium-dose group (I-5 (20 mg / kg)) and compound I-5 high-dose group (I-5 (40 mg / kg)) 2 hours after administration.
[0038] Figure 3 It is the area under the curve of the blank group (Blank), model group (Model), allopurinol group (Allopurinol (40 mg / kg)), low-dose group of compound I-5 (I-5 (10 mg / kg)), medium-dose group of compound I-5 (I-5 (20 mg / kg)) and high-dose group of compound I-5 (I-5 (40 mg / kg)) 6 hours after administration. DETAILED DESCRIPTION
[0039] The carboxyl chalcone derivatives and the preparation method and application thereof of the present invention are further described by way of examples. It is necessary to point out that the following examples are only used to further illustrate the present invention and cannot be understood as limiting the scope of protection of the present invention. Those skilled in the art can make some non-essential improvements and adjustments to the present invention according to the above invention content and implement them specifically, which still falls within the scope of protection of the invention.
[0040] Example 1
[0041] In this example, compound I-1 was synthesized. The synthesis route is shown in the following formula. The specific steps are as follows:
[0042]
[0043] 2.4 mmol of p-methylacetophenone (Compound 1-1) was dissolved in 20 mL of methanol to obtain a p-methylacetophenone solution. 10 mL of a 20 wt% potassium hydroxide solution was added dropwise to the p-methylacetophenone solution, and then 2 mmol of 3-formyl-4-hydroxybenzoic acid methyl ester (Compound 3) was added and mixed evenly. The mixture was reacted at 80°C and 200 W microwave conditions for 2 hours. During the reaction, the reaction was monitored by TLC. After the reaction was completed, the solvent methanol was removed, pure water was added to dissolve the reaction product and washed with ethyl acetate, the aqueous phase was retained, the pH value of the aqueous phase was adjusted to 5-6 with a 1 mol / L HCl solution, and then extracted with ethyl acetate. The organic layer obtained by extraction was washed with a saturated NaCl solution, dried with anhydrous Na2SO4, and evaporated to remove the solvent to obtain a crude product. The crude product was separated and purified by silica gel column chromatography, and gradient elution was performed using a dichloromethane-methanol mixture as the eluent (in the dichloromethane-methanol mixture used in the gradient elution, the volume ratio of dichloromethane to methanol gradually changed from 70:1 to 30:1) to obtain compound I-1. Compound I-1 was a yellow solid with a yield of 70.8% and a HPLC purity of 95.8%.
[0044] Compound I-1 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0045] 1 H NMR (400MHz, DMSO-d6): δ11.36(s,1H),8.37(d,J=2.0Hz,1H),8.03(d,J=8.0Hz,2H),7.99(d,J=16.0Hz,1H),7 .89(d,J=16.0Hz,1H),7.84(dd,J=8.8,2.0Hz,1H),7.37(d,J=8.0Hz,2H),7.13(d,J=8.8Hz,1H),2.40(s,3H). 13 C NMR (100MHz, DMSO-d6): δ188.92,166.97,161.09,143.46,138.33,135.23 ,132.98,130.40,129.39,128.65,122.01,121.93,121.32,116.24,21.22. ESI-HRMS:m / z calcd.for C 17 H 15 O4[M+H] + 283.0970, found 283.0967.
[0046] Example 2
[0047] In this example, compound I-2 was synthesized. The preparation method was basically the same as that in Example 1, except that the raw material p-methylacetophenone was replaced with p-ethylacetophenone. Compound I-2 prepared in this example was a yellow solid with a yield of 50.7% and an HPLC purity of 97.0%. The structure of compound I-2 is as follows:
[0048]
[0049] Compound I-2 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0050] 1 H NMR (400MHz, DMSO-d6): δ8.20(d,J=2.0Hz,1H),8.01(d,J=15.6Hz,1H),7.97(d,J=8.0Hz,2H),7.85(d,J=15.6Hz,1H), 7.75 (dd, J = 8.4, 2.0 Hz, 1H), 7.38 (d, J = 8.0 Hz, 2H), 6.85 (d, J = 8.4 Hz, 1H), 2.69 (q, J = 7.6 Hz, 2H), 1.21 (t, J = 7.6 Hz, 3H). 13 C NMR (100MHz, DMSO-d6): δ189.22,169.49,149.11,141.14,136.00,133.28,130.66,128.50,128.23,120.36,119.71,116.47,28.26,15.29. ESI-HRMS:m / z calcd.for C 14 H 17 O4[M+H] + 297.1127, found 297.1120.
[0051] Example 3
[0052] In this example, compound I-3 was synthesized. The preparation method was basically the same as that in Example 1, except that the raw material p-methylacetophenone was replaced with p-propylacetophenone. Compound I-3 prepared in this example was a yellow solid with a yield of 68.4% and an HPLC purity of 95.9%. The structure of compound I-3 is as follows:
[0053]
[0054] Compound I-3 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0055] 1 H NMR (400MHz, DMSO-d6): δ8.38(d,J=2.0Hz,1H),8.07–7.98(m,3H),7.92–7.83(m,2H),7.37(d,J=8. 0Hz, 2H), 7.02 (d, J = 8.8Hz, 1H), 2.64 (t, J = 7.6Hz, 2H), 1.62 (h, J = 7.6Hz, 2H), 0.90 (t, J = 7.6Hz, 3H). 13 C NMR (100MHz, DMSO-d6): δ188.94,167.49,161.09,147.91,138.50,135.57,13 3.11,130.41,128.80,128.65,121.82,121.27,116.17,37.23,23.84,13.66. ESI-HRMS:m / z calcd.for C 19 H 19 O4[M+H] + 311.1283, found 311.1281.
[0056] Example 4
[0057] In this example, compound I-4 was synthesized. The preparation method was basically the same as that in Example 1, except that the raw material p-methylacetophenone was replaced with p-ethynylacetophenone. Compound I-4 prepared in this example was a yellow solid with a yield of 59.9% and an HPLC purity of 96.0%. The structure of compound I-4 is as follows:
[0058]
[0059] Compound I-4 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0060] 1 H NMR (400MHz, DMSO-d6): δ8.13(d,J=2.4Hz,1H),8.05–7.99(m,3H),7.88(d,J=15.6Hz,1H ), 7.70 (dd, J = 8.8, 2.4Hz, 1H), 7.63 (d, J = 8.0Hz, 2H), 6.70 (d, J = 8.0Hz, 1H), 4.43 (s, 1H). 13C NMR (100MHz, DMSO-d6): δ188.91,169.97,163.57,142.76,138.34,133.60 ,132.11,131.15,128.42,125.69,120.20,118.70,116.91,83.68,82.99. ESI-HRMS:m / zcalcd.for C 14 H 13 O4[M+H] + 293.0814, found 293.0806.
[0061] Example 5
[0062] In this example, compound I-5 was synthesized. The preparation method was basically the same as that in Example 1, except that the raw material p-methylacetophenone was replaced with p-methylaminoacetophenone. Compound I-5 prepared in this example was a yellow solid with a yield of 62.9% and an HPLC purity of 95.2%. The structure of compound I-5 is as follows:
[0063]
[0064] Compound I-5 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0065] 1 H NMR (400MHz, DMSO-d6): δ8.34(d,J=2.0Hz,1H),7.96(d,J=8.8Hz,2H),7.91(d,J=15.6Hz,1H),7.87–7 .81(m,2H),7.00(d,J=8.8Hz,1H),6.71(q,J=4.8Hz,1H),6.61(d,J=8.8Hz,2H),2.77(d,J=4.8Hz,3H). 13 C NMR (100MHz, DMSO-d6): δ186.12,167.05,160.58,153.91,135.98,132.50 ,130.97,130.00,125.31,122.36,121.97,121.85,116.03,110.75,29.19. ESI-HRMS:m / z calcd.for C 17 H 16 NO4[M+H] + 298.1079, found 298.1072.
[0066] Example 6
[0067] In this example, compound I-6 was synthesized. The preparation method was basically the same as that in Example 1, except that the raw material p-methylacetophenone was replaced with p-dimethylaminoacetophenone. Compound I-6 prepared in this example was a yellow solid with a yield of 51.8% and an HPLC purity of 96.4%. The structure of compound I-6 is as follows:
[0068]
[0069] Compound I-6 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0070] 1 H NMR (400MHz, CD3OD): δ8.38(d,J=2.0Hz,1H),8.10(d,J=15.6Hz,1H),8.01(d,J=9.2H z, 2H), 7.92–7.84 (m, 2H), 6.87 (d, J = 8.4Hz, 1H), 6.77 (d, J = 9.2Hz, 2H), 3.07 (s, 6H). 13 C NMR (100MHz, CD3OD): δ190.51,174.31,160.73,155.37,139.77,133.94,132.08,131.40,129.53,126.80,122.75,122.73,116.29,112.02,40.12. ESI-HRMS:m / z calcd.forC 14 H 18 NO4[M+H] + 312.1236, found 312.1236.
[0071] Example 7
[0072] In this example, compound I-7 was synthesized. The preparation method was basically the same as that in Example 1, except that the raw material p-methylacetophenone was replaced with p-methylthioacetophenone. Compound I-7 prepared in this example was a yellow solid with a yield of 51.8% and an HPLC purity of 97.3%. The structure of compound I-7 is as follows:
[0073]
[0074] Compound I-7 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0075] 1H NMR (400MHz, DMSO-d6): δ8.22(d,J=2.0Hz,1H),8.03–7.97(m,3H),7.85(d,J=15.6Hz,1H ), 7.76 (dd, J=8.8, 2.1Hz, 1H), 7.39 (d, J=8.4Hz, 2H), 6.88 (d, J=8.4Hz, 1H), 2.55 (s, 3H). 13 C NMR (100MHz, DMSO-d6): δ188.39,169.17,144.99,140.50,134.28,133.14,130.57,128.84,125.04,120.40,120.01,116.20,14.00. ESI-HRMS:m / z calcd.forC 17 H 14 NaO4S[M+Na] + 337.0510, found 337.0503.
[0076] Example 8
[0077] In this example, compound I-8 was synthesized. The preparation method was basically the same as that in Example 1, except that the raw material p-methylacetophenone was replaced with p-methylsulfonylacetophenone. Compound I-8 prepared in this example was a yellow solid with a yield of 85.6% and an HPLC purity of 99.5%. The structure of compound I-8 is as follows:
[0078]
[0079] Compound I-8 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0080] 1 H NMR (400MHz, DMSO-d6): δ8.27–8.20(m,3H),8.11–8.05(m,3H),7.88(d,J=15.6Hz,1H),7.76(dd,J=8.8,2.0Hz,1H),6.84(d,J=8.8Hz,1H),3.29(s,3H). 13 C NMR (100MHz, DMSO-d6): δ189.16,169.16,143.60,142.45,133.64,131.25,129.02,127.42,120.24,118.85,117.25,43.33. ESI-HRMS:m / z calcd.for C 17 H 14NaO6S[M+Na] + 369.0409, found 369.0402.
[0081] Example 9
[0082] In this example, compound II-1 was synthesized. The synthesis route is shown in the following formula. The specific steps are as follows:
[0083]
[0084] 2.4mmol of 3-acetylthiophene (Compound 2-1) was dissolved in 20mL of methanol to obtain a p-methylacetophenone solution. 10mL of a 20wt% potassium hydroxide solution was added dropwise to the p-methylacetophenone solution, and then 2mmol of 3-formyl-4-hydroxybenzoic acid methyl ester (Compound 3) was added and mixed evenly. The mixture was reacted at 80°C and 200W microwave conditions for 2 hours. During the reaction, the reaction was monitored by TLC. After the reaction was completed, the solvent methanol was removed, pure water was added to dissolve the reaction product and washed with ethyl acetate, the aqueous phase was retained, the pH value of the aqueous phase was adjusted to 5-6 with a 1mol / L HCl solution, and then extracted with ethyl acetate. The organic layer obtained by extraction was washed with a saturated NaCl solution, dried with anhydrous Na2SO4, and evaporated to remove the solvent to obtain a crude product. The crude product was separated and purified by silica gel column chromatography, and gradient elution was performed using a dichloromethane-methanol mixture as the eluent (in the dichloromethane-methanol mixture used in the gradient elution, the volume ratio of dichloromethane to methanol gradually changed from 70:1 to 30:1) to obtain compound II-1. Compound II-1 is a yellow solid with a yield of 41.7% and a HPLC purity of 99.7%.
[0085] Compound II-1 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0086] 1 H NMR (400MHz, DMSO-d6): δ11.10(s,1H),8.85(t,J=2.0Hz,1H),8.42(d,J=2.0Hz,1H),8.01(d,J=16.0Hz ,1H),7.86(dd,J=8.4,2.0Hz,1H),7.82(d,J=16.0Hz,1H),7.66(t,J=2.0Hz,2H),7.01(d,J=8.4Hz,1H). 13C NMR (100MHz, DMSO-d6): δ183.23,166.98,160.82,142.90,137.37,134.37,133.10,130.04,127.60,127.16,122.85,122.04,121.31,116.11. ESI-HRMS:m / z calcd.for C 14 H 10 O4S[M+H] + 275.0378, found 275.0371.
[0087] Example 10
[0088] In this example, compound II-2 was synthesized. The preparation method was basically the same as that in Example 9, except that the raw material 3-acetylthiophene was replaced with 2-acetylthiazole. Compound II-2 prepared in this example was a yellow solid with a yield of 45.5% and an HPLC purity of 96.0%. The structure of compound II-2 is as follows:
[0089]
[0090] Compound II-2 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0091] 1 H NMR (400MHz, DMSO-d6): δ8.25(d,J=3.2Hz,2H),8.21(d,J=3.2Hz,1H),8.14(d,J=16. 0Hz, 1H), 8.05 (d, J = 16.0Hz, 1H), 7.88 (dd, J = 8.4, 2.0Hz, 1H), 7.05 (d, J = 8.4Hz, 1H). 13 C NMR (100MHz, DMSO-d6): δ181.26,167.83,166.77,161.54,145.24,140.09,133.62,131.15,128.34,122.13,120.83,120.81,116.49. ESI-HRMS:m / z calcd.forC 13 H 10 NO4S[M+H] + 276.0331, found 276.0330.
[0092] Embodiment 11
[0093] In this example, compound II-3 was synthesized. The preparation method was basically the same as that of Example 9, except that the raw material 3-acetylthiophene was replaced with 5-acetyl-2,3-dihydrobenzofuran. Compound II-3 prepared in this example was a yellow solid with a yield of 46.2% and an HPLC purity of 99.2%. The structure of compound II-3 is as follows:
[0094]
[0095] Compound II-3 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0096] 1 H NMR (400MHz, DMSO-d6): δ11.39(s,1H),8.35(d,J=2.0Hz,1H),8.05(d,J=1.6Hz,1H),8.01–7.93(m,2H),7.87(d,J=15.6Hz, 1H), 7.82 (dd, J = 8.8, 2.0Hz, 1H), 7.16 (d, J = 8.8Hz, 1H), 6.89 (d, J = 8.8Hz, 1H), 4.65 (t, J = 8.8Hz, 2H), 3.26 (d, J = 8.8Hz, 2H). 13 C NMR (100MHz, DMSO-d6): δ187.48,167.02,164.01,161.06,137.63,132.77,130.93,13 0.41,130.25,128.42,126.03,122.04,121.86,121.46,116.24,108.96,72.23,28.46. ESI-HRMS:m / z calcd.for C 14 H 14 NaO5[M+Na] + 333.0739, found 333.0729.
[0097] Example 12
[0098] In this example, compound II-4 was synthesized. The preparation method was basically the same as that in Example 9, except that the raw material 3-acetylthiophene was replaced with 3',4'-methylenedioxyacetophenone. Compound II-4 prepared in this example was a yellow solid with a yield of 48.1% and an HPLC purity of 96.7%. The structure of compound II-4 is as follows:
[0099]
[0100] Compound II-41 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0101] 1 H NMR (400MHz, DMSO-d6): δ8.21(d,J=2.0Hz,1H),7.99(d,J=15.6Hz,1H),7.83(d,J=15.6Hz,1H),7.74(ddd ,J=8.4,4.4,2.0Hz,2H),7.54(d,J=1.6Hz,1H),7.05(d,J=8.4Hz,1H),6.85(d,J=8.4Hz,1H),6.14(s,2H). 13 C NMR (100MHz, DMSO-d6): δ187.54,169.30,151.16,147.98,140.89,133.09, 132.96,131.01,124.53,120.38,119.28,116.48,108.10,107.67,101.99. ESI-HRMS:m / z calcd.for C 17 H 13 O6[M+H] + 313.0712, found 313.0709.
[0102] Embodiment 13
[0103] In this example, compound II-5 was synthesized. The preparation method was basically the same as that in Example 9, except that the raw material 3-acetylthiophene was replaced with 6-acetyl-1,4-benzodioxetane. Compound II-5 prepared in this example was a yellow solid with a yield of 48.9% and an HPLC purity of 97.5%. The structure of compound II-5 is as follows:
[0104]
[0105] Compound II-5 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0106] 1H NMR (400MHz, DMSO-d6): δ11.21(s,1H),8.39(d,J=2.0Hz,1H),7.97(d,J=15.6Hz,1H),7.88(d,J=15.6Hz,1H),7.85–7.82(m,1 H), 7.71 (dd, J = 8.4, 2.0Hz, 1H), 7.65 (d, J = 2.0Hz, 1H), 7.05 (d, J = 8.8Hz, 1H), 7.01 (d, J = 8.4Hz, 1H), 4.34 (s, 2H), 4.31 (s, 2H). 13 C NMR (100MHz, DMSO-d6): δ187.49,166.97,160.90,147.92,143.40,137.88,132.92,13 1.31,130.39,122.66,121.97,121.83,121.40,117.44,117.19,116.11,64.59,63.96. ESI-HRMS:m / z calcd.for C 14 H 15 O6[M+H] + 327.0869, found 327.0862.
[0107] Embodiment 14
[0108] In this example, compound II-6 was synthesized. The preparation method was basically the same as that of Example 9, except that the raw material 3-acetylthiophene was replaced with 1-(2,3-dihydro-1H-indol-5-yl)-ethanone. Compound II-6 prepared in this example was a yellow solid with a yield of 43.2% and an HPLC purity of 99.3%. The structure of compound II-6 is as follows:
[0109]
[0110] Compound II-6 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0111] 1 H NMR (400MHz, DMSO-d6): δ8.21(s,1H),7.93(d,J=15.6Hz,1H),7.82–7.72(m,4H),6.91 (d, J=8.4Hz, 1H), 6.50 (d, J=8.4Hz, 1H), 3.56 (t, J=8.8Hz, 2H), 3.00 (t, J=8.8Hz, 2H). 13C NMR (100MHz, DMSO-d6): δ186.37,169.41,156.97,138.34,132.50,130.34,12 9.98,128.89,126.99,124.80,120.73,120.38,115.93,106.27,46.29,28.12. ESI-HRMS:m / z calcd.for C 14 H 16 NO4[M+H] + 310.1079, found 310.1079.
[0112] Embodiment 15
[0113] In this example, compound II-7 was synthesized. The preparation method was basically the same as that in Example 9, except that the raw material 3-acetylthiophene was replaced with 5-acetylindole. Compound II-7 prepared in this example was a yellow solid with a yield of 48.9% and a HPLC purity of 99.4%. The structure of compound II-7 is as follows:
[0114]
[0115] Compound II-7 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0116] 1 H NMR (400MHz, DMSO-d6): δ11.50(s,1H),8.53(s,1H),8.40(d,J=2.0Hz,1H),8.15(s,1H),8.02(d,J=16.0Hz,1H),8.01(d,J=16.0Hz,1H),7.89( dd,J=8.8,2.0Hz,1H),7.85(dd,J=8.4,2.0Hz,1H),7.51(d,J=8.8Hz,1H),7.48(t,J=2.4Hz,1H),7.02(d,J=8.4Hz,1H),6.65(t,J=2.4Hz,1H). 13 C NMR (100MHz, DMSO-d6): δ188.87,167.04,160.72,138.52,136.96,132.73,130.12,129 .55,127.33,127.16,122.78,122.59,122.06,121.68,121.58,116.08,111.64,103.12. ESI-HRMS:m / z calcd.for C 14 H14 NO4[M+H] + 308.0923, found 308.0924.
[0117] Example 16
[0118] In this example, compound II-8 was synthesized. The preparation method was basically the same as that of Example 9, except that the raw material 3-acetylthiophene was replaced with 6-acetylquinoline. Compound II-8 prepared in this example was a yellow solid with a yield of 33.3% and an HPLC purity of 97.6%. The structure of compound II-8 is as follows:
[0119]
[0120] Compound II-8 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0121] 1 H NMR (400MHz, DMSO-d6): δ9.26(dd,J=4.8,1.6Hz,1H),9.15(d,J=2.0Hz,1H),9.06(d,J=8.0Hz,1H),8.55(dd,J=8.8,2.0Hz,1H),8.46(d,J=2.0Hz,1H), 8.36(d,J=8.8Hz,1H),8.14(d,J=16.0Hz,1H),8.06(d,J=16.0Hz,1H),7.98 (dd, J=8.4, 4.8Hz, 1H), 7.88 (dd, J=8.8, 2.0Hz, 1H), 7.10 (d, J=8.8Hz, 1H). 13 C NMR (100MHz, DMSO-d6): δ188.61,166.99,161.25,149.66,143.55,139.51,136.59,133 .53,130.80,130.69,130.32,128.01,125.24,122.82,122.08,121.55,121.19,116.35. ESI-HRMS:m / z calcd.for C 19 H 14 NO4[M+H] + 320.0923, found 320.0914.
[0122] Embodiment 17
[0123] In this example, compound II-9 was synthesized. The preparation method was basically the same as that of Example 9, except that the raw material 3-acetylthiophene was replaced with 2-acetylnaphthalene. Compound II-9 prepared in this example was a yellow solid with a yield of 51.6% and an HPLC purity of 97.9%. The structure of compound II-9 is as follows:
[0124]
[0125] Compound II-9 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0126] 1 H NMR (400MHz, DMSO-d6): δ8.83(d,J=1.6Hz,1H),8.36(d,J=2.0Hz,1H),8.23–7.9 8(m,6H),7.83(dd,J=8.8,2.0Hz,1H),7.70–7.59(m,2H),7.00(d,J=8.8Hz,1H). 13 CNMR (100MHz, DMSO-d6): δ189.37,168.70,163.26,140.80,135.49,134.92,133.31,132.39 ,130.51,129.87,129.71,128.49,128.42,127.68,126.88,124.27,120.73,119.95,116.65. ESI-HRMS:m / z calcd.for C 20 H 15 O4[M+H] + 319.0970, found 319.0963.
[0127] Embodiment 18
[0128] In this example, compound II-10 was synthesized. The preparation method was basically the same as that in Example 9, except that the raw material 3-acetylthiophene was replaced with 1-acetylnaphthalene. Compound II-10 prepared in this example was a yellow solid with a yield of 57.1% and a HPLC purity of 97.6%. The structure of compound II-10 is as follows:
[0129]
[0130] Compound II-10 1 H NMR and 13 The results of C NMR and mass spectrometry are as follows:
[0131] 1 H NMR (400MHz, DMSO-d6): δ8.20(dd,J=6.4,3.2Hz,1H),8.10(d,J=8.4Hz,1H),8.06(s,1H),8.02(dd,J=6.4,3.2Hz,1H),7.82–7.75(m ,2H),7.69(dd,J=8.8,2.0Hz,1H),7.63(d,J=8.4Hz,1H),7.58(dt,J=6.4,3.2Hz,2H),7.48(d,J=16.0Hz,1H),6.73(d,J=8.8Hz,1H). 13 C NMR (100MHz, DMSO-d6): δ195.35,169.08,143.55,137.46,133.36,131.01,130.82, 129.91,128.47,127.17,126.68,126.36,125.34,124.98,124.24,119.92,117.07. ESI-HRMS:m / zcalcd.for C 20 H 15 O4[M+H] + 319.0970, found 319.0962.
[0132] Comparative Example 1
[0133] In this comparative example, compound D1 was synthesized in the following steps:
[0134] 2.4 mmol of p-methylacetophenone (Compound 1-1) was dissolved in 20 mL of methanol to obtain a p-methylacetophenone solution. 10 mL of a 20 wt% potassium hydroxide solution was added dropwise to the p-methylacetophenone solution, and then 2 mmol of methyl p-formylbenzoate was added and mixed evenly. The mixture was reacted at 80°C and 200 W microwave conditions for 2 hours. During the reaction, the reaction was monitored by TLC. After the reaction was completed, the solvent methanol was removed, pure water was added to dissolve the reaction product and washed with ethyl acetate, the aqueous phase was retained, the pH value of the aqueous phase was adjusted to 5-6 with a 1 mol / L HCl solution, and then extracted with ethyl acetate. The organic layer obtained by extraction was washed with a saturated NaCl solution, dried with anhydrous Na2SO4, and evaporated to remove the solvent to obtain a crude product. The crude product was separated and purified by silica gel column chromatography, and gradient elution was performed using a dichloromethane-methanol mixture as the eluent (in the dichloromethane-methanol mixture used in the gradient elution, the volume ratio of dichloromethane to methanol gradually changed from 70:1 to 30:1) to obtain compound D1. Compound D1 is a yellow solid with a yield of 78.7% and a HPLC purity of 95%. The structural formula of compound D1 is as follows:
[0135]
[0136] Compound D1 1 The results of H NMR are as follows:
[0137] 1 H NMR (400MHz, DMSO-d6): δ8.15(m,2H),8.03(d,J=8.0Hz,2H),7.94(d,J=16.0Hz,1H),7.75(d,J =16.0Hz, 1H), 7.94 (t, J = 8.8Hz, 1H), 7.34 (d, J = 8.0Hz, 2H), 7.13 (t, J = 7.6Hz, 1H), 2.41 (s, 3H).
[0138] Comparative Example 2
[0139] In this comparative example, compound D2 was synthesized. The preparation method was basically the same as that of comparative example 1, except that the raw material p-methylacetophenone was replaced with 3',4'-methylenedioxyacetophenone. Compound D2 prepared in this example was a yellow solid with a yield of 67.5% and an HPLC purity of 97.2%. The structure of compound D2 is as follows:
[0140]
[0141] Compound D1 1 The results of H NMR are as follows:
[0142] 1 H NMR (400MHz, DMSO-d6) δ8.45(d,J=2.0Hz,1H),8.24(d,J=2.0Hz,1H),7.96–7.85(m,2H),7.71(d,J=15.6Hz, 1H), 7.65 (d, J = 1.6Hz, 1H), 7.39 (t, J = 7.6Hz, 1H), 7.31 (t, J = 7.6Hz, 1H), 7.08 (d, J = 8.0Hz, 1H), 6.16 (s, 2H).
[0143] Embodiment 19
[0144] In this example, a xanthine oxidase (XO) inhibitor screening model was used to detect the in vitro XO inhibition activity of carboxychalcone derivatives (i.e., compounds I-1 to I-8, compounds II-1 to II-10, and compounds D1 to D2), with allopurinol and febuxostat as positive control drugs, respectively, and the operation was as follows:
[0145] (1) Preparation of pH 7.4 phosphate buffer solution (PBS solution): weigh 15.6 g of Na2HPO4·12H2O, add deionized water to 1000 mL to dissolve, and obtain Na2HPO4 solution; weigh 17.8 g of NaH2PO4·2H2O, add deionized water to 1000 mL to dissolve, and obtain NaH2PO4 solution; take 19 mL of NaH2PO4 solution and 81 mL of Na2HPO4 solution, mix thoroughly, and adjust the pH to 7.4 to obtain 0.1 mol·L -1 PBS solution, stored at room temperature.
[0146] (2) Preparation of substrate xanthine: Place xanthine in a 50 mL volumetric flask and dissolve in 1 mL of 0.1 mol / L NaOH solution. Adjust the pH to 7.4 with dilute hydrochloric acid and add PBS solution to make the volume to 50 mL to obtain a 0.5 mmol / L xanthine solution.
[0147] (3) Preparation of XO solution: XO was prepared into a 0.08 U / mL XO solution using PBS solution.
[0148] (4) Preparation of XO inhibitor solution: accurately weigh compounds I-1 to I-8, compounds II-1 to II-10, compounds D1 to D2, allopurinol, and febuxostat, dissolve them in DMSO to prepare a 10 mmol / L stock solution, store at -20°C, and dilute with PBS solution to the required concentration (0.1 to 20 μmol / L) before use.
[0149] (5) Inhibition experiment of each test compound on XO
[0150] In a 200 μL reaction system, add 50 μL XO (final concentration 0.025 U mL -1 ) and 100 μL of different concentrations of XO inhibitor solutions (i.e., solutions of compounds I-1 to I-8, compounds II-1 to II-10, compounds D1 to D2, allopurinol, and febuxostat) were incubated at 37°C for 30 min. Subsequently, 50 μL of 0.5 mmol·L -1 The experiment was carried out with xanthine as the substrate. The absorbance of the mixture system was measured every 15 seconds at a wavelength of 295 nm, and the total measurement time was 5 minutes. Allopurinol and febuxostat were used as positive controls, and blank PBS solution was used as negative control. Each group was measured three times in parallel.
[0151] Add 50 μL of 0.08 U / mL XO solution and 100 μL of different concentrations of chalcone derivative solution or positive control drug solution to a 96-well microplate and incubate at 37°C for 30 minutes. Subsequently, add 50 μL of 0.5 mmol / L xanthine solution to start the reaction. Measure the absorbance value at a wavelength of 295 nm on an ELISA reader at regular intervals and draw an inhibition curve. GraphPad Prism 9 software was used to calculate the half-maximal inhibition concentration IC 50 The results are shown in Table 1.
[0152] Table 1 In vitro inhibition of XO activity by carboxychalcone derivatives
[0153]
[0154] a Data are means ± SD of three independent repeated experiments.
[0155] As shown in Table 1, the structural difference between compound D1 and compound I-1 is that compound I-1 introduces hydroxyl group and carboxyl group at the ortho and meta positions of chalcone B ring, while compound D1 introduces hydroxyl group at the chalcone B ring. However, compound I-1 has a significantly lower IC 50 value, that is, compound I-1 has significantly better XO inhibition activity; similarly, the difference between compound D2 and compound II-4 is that compound II-4 introduces hydroxyl groups and carboxyl groups at the ortho and meta positions of the chalcone B ring, while compound D2 does not introduce a hydroxyl group on the chalcone B ring, and compound II-4 has a significantly lower IC 50 The value of 1:1 indicates that compound II-4 has significantly better XO inhibitory activity. This indicates that the simultaneous modification of hydroxyl group and carboxyl group at the ortho and meta positions of the B ring of chalcone can effectively enhance the XO inhibitory activity of carboxyl chalcone derivatives compared with the case where only the carboxyl group is modified on the B ring of chalcone.
[0156] It can also be seen from Table 1 that compared with allopurinol, which is currently widely used in clinical practice, the carboxyl chalcone derivatives (compounds I-1 to I-8, compounds II-1 to II-10) provided in the present application have significantly better XO inhibitory activity, and their IC 50 The value is significantly smaller, which is similar to the allopurinol IC 50 The difference in the values is more than one order of magnitude. Meanwhile, the XO inhibition activities of compounds I-2, I-5 and II-6 in vitro are close to those of Febuxostat.
[0157] Embodiment 20
[0158] In this example, the effects of carboxychalcone derivatives on serum uric acid in acute hyperuricemia model rats were investigated.
[0159] The experimental animals used in the animal experiment were 6-week-old male SD rats (200±20 g) from the Experimental Animal Center of Sichuan University. The acute hyperuricemia model was constructed by intraperitoneal injection of potassium oxonate (PO) to increase the uric acid level. Allopurinol was used as a positive control. The rats were adaptively fed for one week in an animal room with a light / dark cycle of 12h:12h, temperature and humidity controlled, and fasted but not water for 12h the day before the experiment. Initially, all rats were randomly divided into six groups (n=7): blank group, model group, allopurinol group, low-dose group of compound I-5, medium-dose group of compound I-5 and high-dose group of compound I-5, as shown in Table 2. Except for the blank group injected with normal saline, all rats were intraperitoneally injected with PO (300 mg / kg). After 1h, the rats in the blank group and the model group were gavaged with 0.5% CMC-Na, and the rats in the other groups were gavaged with the corresponding dose of the compound. After 1h, 2h, 3h, 4h, 6h, and 8h of administration, about 200-300 μL of blood samples were collected from each rat by orbital bleeding, and serum was obtained by centrifugation at 3000 r / min at 4°C. Serum uric acid was determined according to the instructions of the kit (Nanjing Jiancheng Bioengineering Institute, China). Time-effect curves were drawn based on the serum uric acid concentrations of rats in each group.
[0160] Table 2 Scheme for determination of serum uric acid content in rats with hyperuricemia model
[0161]
[0162] The experimental results of this embodiment are as follows Figures 1 to 3 As shown, Figure 1 is a curve showing the change of serum uric acid concentration over time after administration of the blank group, model group, allopurinol group (Allopurinol (40 mg / kg)), compound I-5 low-dose group (I-5 (10 mg / kg)), compound I-5 medium-dose group (I-5 (20 mg / kg)) and compound I-5 high-dose group (I-5 (40 mg / kg)), Figure 2 The serum uric acid concentration ( ) of the blank group, model group, allopurinol group (Allopurinol (40 mg / kg)), compound I-5 low-dose group (I-5 (10 mg / kg)), compound I-5 medium-dose group (I-5 (20 mg / kg)) and compound I-5 high-dose group (I-5 (40 mg / kg)) after 2 hours of administration was #### p<0.0001vs blank; ****p<0.0001,***p<0.001,**p<0.005,*p<0.05vs model), Figure 3The area under the curve (AUC) of the blank group, model group, allopurinol group (Allopurinol (40 mg / kg)), low-dose group of compound I-5 (I-5 (10 mg / kg)), medium-dose group of compound I-5 (I-5 (20 mg / kg)) and high-dose group of compound I-5 (I-5 (40 mg / kg)) after 6 hours of administration was #### p<0.0001vs blank; ****p<0.0001,***p<0.001,**p<0.005,*p<0.05vsmodel).
[0163] Depend on Figures 1 to 3 It can be seen that compared with the blank group, the serum uric acid level in the model group remained at a higher level after intraperitoneal injection of PO (300 mg / kg) ( #### p<0.0001), which proves that the model of acute hyperuricemia was successfully induced. When compound I-5 was orally administered at a dose of 10 mg / kg, it showed a certain uric acid-lowering effect, which was less different from the model group ( * p<0.05). When compound I-5 was orally administered at a dose of 20 mg / kg, it showed a general uric acid-lowering effect compared with the model group ( ** p<0.005). When compound I-5 was orally administered at a dose of 40 mg / kg, it showed a better uric acid-lowering effect, which was comparable to that of the positive control group. The serum uric acid level in this group was significantly different from that in the model group ( **** p<0.0001). This indicates that the carboxyl chalcone derivatives (e.g., compound I-5) provided by the present invention can significantly inhibit the serum uric acid index of hyperuricemia in vivo, exert good anti-hyperuricemia activity, and its therapeutic effect is proportional to the dose.
[0164] The above experimental results indicate that the carboxyl chalcone derivatives provided by the present invention have good XO inhibitory activity and uric acid-lowering ability in vivo, can reduce serum uric acid levels, and have broad prospects in the development of anti-hyperuricemia drugs.
Claims
1. A carboxychalcone derivative, characterized in that: The general structural formula of the carboxyl chalcone derivative is shown in formula (I) or formula (II): In formula (I), R1 is methyl, ethyl, n-propyl, ethynyl, methylamino, dimethylamino, methylthio or methylsulfonyl; In formula (II), R2 is 3-thiophene, 2-thiazole, dihydrobenzofuran, benzodioxolane, benzodioxane, indole, dihydroindole, quinoline or naphthalene.
2. The carboxychalcone derivative according to claim 1, characterized in that: The carboxy chalcone derivatives with the general structural formula shown in formula (I) or formula (II) are in the trans (E) configuration.
3. The carboxychalcone derivative according to claim 1, characterized in that: The carboxy chalcone derivatives having a general structural formula as shown in formula (II) include compounds II-1 to II-10, and the structural formulas of compounds II-1 to II-10 are as follows:
4. A pharmaceutically acceptable salt of the carboxychalcone derivative according to any one of claims 1 to 3.
5. The method for preparing the carboxychalcone derivatives according to any one of claims 1 to 3, characterized in that: The synthetic route and steps are as follows: ① dissolving compound 1 or compound 2 in a solvent to obtain a solution of compound 1 or compound 2, adjusting the pH value of the solution of compound 1 or compound 2 to 9-13, then adding 3-formyl-4-hydroxybenzoic acid methyl ester and mixing evenly to obtain a reaction precursor solution, and fully reacting under microwave conditions of 80-100° C. and 100-300W; The compound 1 is p-methylacetophenone, p-ethylacetophenone, p-propylacetophenone, p-ethynylacetophenone, p-methylaminoacetophenone, p-dimethylaminoacetophenone, p-methylthioacetophenone or p-methylsulfonylacetophenone; the compound 2 is 3-acetylthiophene, 2-acetylthiazole, 5-acetyl-2,3-dihydrobenzofuran, 3',4'-methylenedioxyacetophenone, 6-acetyl-1,4-benzodioxetane, 1-(2,3-dihydro-1H-indol-5-yl)-ethanone, 5-acetylindole, 6-acetylquinoline, 2-acetylnaphthalene or 1-acetylnaphthalene; In this step, the molar ratio of compound 1 or compound 2 to methyl 3-formyl-4-hydroxybenzoate is controlled to be (1-1.5):1; ② removing the solvent of the reaction solution obtained after the reaction in step ① is completed to obtain a reaction product, dissolving the reaction product in water and washing it with ethyl acetate, adjusting the pH value of the obtained aqueous phase to 5-6, and then extracting it with ethyl acetate, washing the extracted organic phase with a saturated sodium chloride solution, then removing water, and evaporating to remove ethyl acetate to obtain a crude product; separating and purifying the crude product by silica gel column chromatography to obtain a carboxy chalcone derivative.
6. The method for preparing the carboxychalcone derivatives according to claim 5, characterized in that: In step ②, when the crude product is separated and purified by silica gel column chromatography, gradient elution is performed using a dichloromethane-methanol mixture as an eluent. In the dichloromethane-methanol mixture used for gradient elution, the volume ratio of dichloromethane to methanol gradually changes from 70:1 to 30:
1.
7. The method for preparing the carboxychalcone derivatives according to claim 5 or 6, characterized in that: The solvent in step ① is water, methanol or ethanol.
8. The method for preparing the carboxychalcone derivatives according to claim 5 or 6, characterized in that: In the reaction precursor solution in step ①, the concentration of compound 1 or compound 2 is 0.05-0.1 mmol / mL.
9. Use of the carboxychalcone derivatives according to any one of claims 1 to 3 or the pharmaceutically acceptable salts of the carboxychalcone derivatives according to any one of claims 1 to 3 in the preparation of drugs targeting xanthine oxidase.
10. The use according to claim 9, characterized in that: The drug targeting xanthine oxidase includes a drug for treating hyperuricemia.
Citation Information
Patent Citations
Preparation method and application of ethyl 2-(4-hydroxyphenyl)thiazole-4-carboxylate derivatives
CN106749090A
Synthetic method of chalcone derivative and application of chalcone derivative in medicine for treating COPD and other lung inflammations
CN113773188A
2 '-halogenated chalcone derivative as well as preparation method, pharmaceutical composition and application thereof
CN113979851A
